Summary of opinion: Ofev, 12/12/2024 Positive
Submitted by Anonymous (not verified) on 13 December 2024 - 11:00
Summary of opinion: Ofev, 12/12/2024 Positive
Summary of opinion: Omvoh, 12/12/2024 Positive
Submitted by Anonymous (not verified) on 13 December 2024 - 11:00
Summary of opinion: Omvoh, 12/12/2024 Positive
Summary of opinion: Jemperli, 12/12/2024 Positive
Submitted by Anonymous (not verified) on 13 December 2024 - 11:00
Summary of opinion: Jemperli, 12/12/2024 Positive
Summary of opinion: Blincyto, 12/12/2024 Positive
Submitted by Anonymous (not verified) on 13 December 2024 - 11:00
Summary of opinion: Blincyto, 12/12/2024 Positive
First medicine to treat rare genetic disorder causing cysts and tumours
Submitted by Anonymous (not verified) on 13 December 2024 - 11:00
First medicine to treat rare genetic disorder causing cysts and tumours
Summary of opinion: Vocabria, 12/12/2024 Positive
Submitted by Anonymous (not verified) on 13 December 2024 - 11:00
Summary of opinion: Vocabria, 12/12/2024 Positive
Alofisel withdrawn from the EU market
Submitted by Anonymous (not verified) on 13 December 2024 - 11:00
Alofisel withdrawn from the EU market
First treatment recommended for rare progressive lung conditions in children and adolescents
Submitted by Anonymous (not verified) on 13 December 2024 - 10:14
First treatment recommended for rare progressive lung conditions in children and adolescents
Human medicines European public assessment report (EPAR): Rydapt, midostaurin, Date of authorisation: 18/09/2017, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 12 December 2024 - 16:16
Human medicines European public assessment report (EPAR): Rydapt, midostaurin, Date of authorisation: 18/09/2017, Revision: 13, Status: Authorised
Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 20, Status: Authorised
Submitted by Anonymous (not verified) on 12 December 2024 - 16:03
Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 20, Status: Authorised